Medications
G-CSF, GM-CSF, anti-IL-5 biologics, corticosteroids, imatinib, and every drug that targets granulocyte number or function.
Pavord et al. anti-IL-5 mepolizumab cut exacerbations in severe eosinophilic asthma.
Ortega et al. MENSA trial of intravenous and subcutaneous mepolizumab in severe eosinophilic asthma.
Bleecker et al. anti-IL-5 receptor alpha benralizumab reduced exacerbations in severe eosinophilic asthma.
Crawford et al. G-CSF reduced febrile neutropenia after chemotherapy.
Dellon et al. anti-IL-4 receptor alpha dupilumab improved histologic and symptom outcomes in EoE.
Campisi et al. pilot study of mepolizumab on mucus plugs in severe eosinophilic asthma, with and without bronchiectasis.
Sciurba et al. NEJM trial of tozorakimab (anti-IL-33) in COPD; IL-33 drives both eosinophilic and neutrophilic airway inflammation.
Harman et al. identify baseline blood eosinophil count and nasal polyp comorbidity as the strongest predictors of response to anti-IL-5 biologics in severe asthma.
Dupilumab reduced eosinophilic otitis media severity over 12 months in severe eosinophilic asthma with nasal polyps; bronchiectasis comorbidity did not blunt the response.